Trial Profile
An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB, REQUIP XL at 2 mg) Manufactured at Crawley and Aranda
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 15 Jun 2011 New trial record